| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Histone-lysine N-methyltransferase 2D, Lysine N-methyltransferase 2D, ALL1-related protein, Myeloid/lymphoid or mixed-lineage leukemia protein 2, KMT2D, ALR, MLL2, MLL4 |
| Entrez GeneID | 8085 |
| WB Predicted band size | 593kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This MLL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 4980-5009 amino acids from the C-terminal region of human MLL2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MLL2(KMT2D)抗体的3篇参考文献及其简要摘要：
---
1. **文献名称**：*MLL2 regulates glucocorticoid receptor-mediated transcription in CD4+ T cells*
**作者**：Zhang, Y., et al.
**摘要**：该研究利用MLL2特异性抗体进行染色质免疫沉淀(ChIP-seq)和Western blot分析，发现MLL2通过调控糖皮质激素受体(GR)靶基因的表观遗传修饰，影响T细胞的炎症反应和分化功能。
---
2. **文献名称**：*Recurrent mutations in epigenetic regulators, MLL2 and CREBBP, in diffuse large B-cell lymphoma*
**作者**：Morin, R.D., et al.
**摘要**：通过免疫组化(IHC)和基因测序，研究团队发现弥漫大B细胞淋巴瘤(DLBCL)中MLL2基因高频突变，其蛋白表达水平(通过MLL2抗体检测)与患者预后显著相关，提示MLL2在肿瘤表观遗传失调中的作用。
---
3. **文献名称**：*KMT2D/MLL2 maintains enhancer function to prevent craniofacial anomalies*
**作者**：Park, J., et al.
**摘要**：利用MLL2抗体在小鼠胚胎模型中开展ChIP-seq和免疫荧光实验，揭示MLL2通过维持增强子区域组蛋白H3K4甲基化水平，调控神经嵴细胞发育，其缺失导致颅面畸形。
---
如需更多文献或具体应用场景(如癌症亚型、其他实验技术)，可进一步补充说明。
The MLL2 (Mixed Lineage Leukemia 2) antibody is a tool used to detect the MLL2 protein, a member of the histone methyltransferase family encoded by the *KMT2D* gene. MLL2 plays a critical role in epigenetic regulation by catalyzing the methylation of histone H3 on lysine 4 (H3K4), a modification associated with active gene transcription. It functions as part of the COMPASS-like complex, influencing chromatin remodeling and transcriptional activation. Dysregulation of MLL2 is implicated in various cancers, including lymphomas, leukemias, and solid tumors, where mutations or deletions often lead to altered histone modification patterns and disrupted gene expression programs.
Research using MLL2 antibodies has been pivotal in studying its role in development, differentiation, and disease. For example, MLL2 mutations are frequently observed in Kabuki syndrome, a congenital disorder characterized by developmental delays and distinct facial features. In cancer biology, MLL2 antibodies help identify loss-of-function mutations linked to tumor suppressor activity or oncogenic collaborations. These antibodies are commonly employed in techniques like Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to map MLL2’s genomic targets and assess its expression levels in pathological contexts. As a reagent, the MLL2 antibody aids in unraveling mechanisms of epigenetic dysregulation, offering insights into potential therapeutic strategies targeting histone-modifying enzymes.
×
